



## Clinical trial results:

### A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients with Idiopathic Pulmonary Fibrosis

#### Summary

EudraCT number	2022-000498-15
Trial protocol	IT CZ ES HU AT PL
Global end of trial date	09 January 2025

#### Results information

Result version number	v1 (current)
This version publication date	25 December 2025
First version publication date	25 December 2025

#### Trial information

##### Trial identification

Sponsor protocol code	RXC007/0002
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	ISRCTN60385283
ClinicalTrials.gov id (NCT number)	NCT05570058
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Redx Pharma Ltd.
Sponsor organisation address	Block 33, Mereside, Alderley Park, Alderley Edge, Cheshire, United Kingdom, SK10 4TG
Public contact	Chief Medical Officer, Redx Pharma Ltd., +44 (0)1625 469900, h.timmis@redxpharma.com
Scientific contact	Chief Medical Officer, Redx Pharma Ltd., +44 (0)1625 469900, h.timmis@redxpharma.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 August 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	05 August 2024
Global end of trial reached?	Yes
Global end of trial date	09 January 2025
Was the trial ended prematurely?	No

Notes:

---

## General information about the trial

Main objective of the trial:

- To assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.

Protection of trial subjects:

The rights, safety and well-being of subjects were protected in accordance with the Declaration of Helsinki, ICH GCP and all applicable regulatory requirements. The protocol, informed consent form and related documents received prior approval from Independent Ethics Committees/Institutional Review Boards before study initiation. Written informed consent was obtained from each participant prior to screening or any protocol-specific procedure, ensuring subjects were fully informed of the study objectives, potential risks and benefits, and their right to withdraw at any time.

A Dose Review Committee (DRC) oversaw subject safety, reviewing data after at least 28 days of dosing in each cohort before dose escalation. Enrolment was paused if two or more subjects experienced similar severe or serious adverse events until the DRC completed a review. Safety monitoring included scheduled physical examinations, vital signs, electrocardiograms, and laboratory assessments. Adverse events, serious adverse events, and adverse events of special interest were collected and reported in accordance with protocol-defined procedures and regulatory timelines.

The protocol included predefined withdrawal and discontinuation criteria to protect participants from undue risk. Subjects who discontinued treatment remained under follow-up for safety evaluation. Data confidentiality was maintained by assigning each participant a unique trial number; no directly identifying information was used in study records. Insurance coverage was provided in line with regulatory requirements to ensure compensation in the event of trial-related injury.

These measures, together with continuous monitoring and oversight, ensured that the rights and safety of all participants were appropriately safeguarded throughout the trial.

Background therapy:

In this study, background therapy for idiopathic pulmonary fibrosis (IPF) was permitted in the form of either nintedanib or pirfenidone, provided the patient had been on a stable dose for at least 8 weeks prior to first administration of the investigational product. Patients could not receive both agents simultaneously, and initiation of background therapy during the study was not permitted; any new start of nintedanib or pirfenidone was considered disease progression and reported as a protocol deviation.

Patients not receiving background IPF therapy at study entry continued without it. Randomisation to RXC007 or placebo occurred independently of background therapy, meaning patients could be randomised while on nintedanib, pirfenidone, or no antifibrotic therapy.

Concomitant medications considered necessary for patient welfare were permitted if judged by the investigator not to interfere with study treatment, and all such medications were recorded in the eCRF. However, several restrictions were imposed. Systemic steroids (other than inhaled or topical) and anticoagulants (except antiplatelet agents) were prohibited throughout the trial

In addition, herbal supplements and medications affecting relevant enzyme systems (e.g., CYP1A2, CYP2B6, CYP3A4) were restricted, and specific drug–drug interaction precautions applied to patients on pirfenidone or nintedanib.

COVID-19 vaccination was permitted before or during study treatment, apart from live-attenuated or replication-competent vector vaccines, which were prohibited within 4 weeks of starting study therapy and during the treatment period

Overall, background therapy was carefully managed to ensure consistency, minimise confounding effects, and maintain patient safety, with strict adherence to predefined restrictions.

#### Evidence for comparator:

This study used placebo as the comparator. The reason for using placebo was to clearly see the effects of RXC007 on patients with idiopathic pulmonary fibrosis (IPF). By comparing RXC007 with placebo, any differences in safety or activity could be directly linked to the study drug, without interference from other treatments.

The design reduced risk for patients on placebo. A 3:1 randomisation meant more patients received RXC007 than placebo, and the double-blind period lasted only 12 weeks, which is short compared to the slow progression of IPF. After this period, all patients had the option to continue in an open-label extension where they could receive RXC007.

Patients could be enrolled whether they were already on a stable background antifibrotic therapy (nintedanib or pirfenidone) or not. Randomisation ensured balance between the groups so that comparisons would be justified.

Placebo was chosen because they gave a clear comparison, reduced bias, and supported reliable measurement of RXC007's effect. The short study period, 3:1 randomisation, and open-label extension ensured patients were not exposed to unnecessary risk while using a placebo in the study.

Actual start date of recruitment	21 July 2022
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

### Population of trial subjects

#### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 4
Country: Number of subjects enrolled	Spain: 6
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	United Kingdom: 25
Country: Number of subjects enrolled	Italy: 9
Country: Number of subjects enrolled	Switzerland: 1
Country: Number of subjects enrolled	Czechia: 2
Worldwide total number of subjects	48
EEA total number of subjects	22

Notes:

#### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	11
From 65 to 84 years	37
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Recruitment began on 08 Nov 2022 and ended on 09 Jan 2025. Patients with IPF were enrolled across European centres and randomised 3:1 to RXC007 or placebo. A total of 49 patients were randomised; 48 received at least one dose of study treatment.

### Pre-assignment

Screening details:

Screening included medical history, physical exam, pulmonary function tests, HRCT confirmation of IPF, vital signs, ECG, and laboratory assessments. Eligibility required stable background therapy if used, and all inclusion/exclusion criteria had to be met before randomisation.

### Pre-assignment period milestones

Number of subjects started	48
Number of subjects completed	48

### Period 1

Period 1 title	12 week period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	RXC007 20 mg

Arm description:

Subjects received RXC007 20 mg twice daily for 12 weeks during the double-blind period and could remain on stable background antifibrotic therapy (nintedanib or pirfenidone) if applicable."

Arm type	Experimental
Investigational medicinal product name	RXC007
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

RXC007 20 mg twice daily. When administered twice daily, RXC007 must be taken approximately 12 hours apart between the morning and evening doses and patients must eat their meal as described above, 30 minutes prior to the evening dose of RXC00

<b>Arm title</b>	RXC007 50 mg
------------------	--------------

Arm description:

Subjects received RXC007 50 mg twice daily for 12 weeks during the double-blind period and could remain on stable background antifibrotic therapy (nintedanib or pirfenidone) if applicable

Arm type	Experimental
Investigational medicinal product name	RXC007
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

RXC007 was administered orally as capsules twice daily (BID) at fixed doses of 20 mg or 50 mg for 12 weeks during the double-blind treatment period.

<b>Arm title</b>	Placebo
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	RXC007
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

Placebo capsules were administered orally twice daily (BID) for 12 weeks during the double-blind treatment period. The placebo was identical in appearance, packaging, and dosing schedule to the RXC007 capsules and was taken approximately 12 hours apart.

<b>Number of subjects in period 1</b>	RXC007 20 mg	RXC007 50 mg	Placebo
Started	18	18	12
Completed	14	16	10
Not completed	4	2	2
Consent withdrawn by subject	2	-	1
Adverse event, non-fatal	2	2	1

**Period 2**

Period 2 title	12 week period _OLE
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	No
<b>Arm title</b>	RXC007 20 mg Open label extension
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	RXC007
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

RXC007 20 mg twice daily. When administered twice daily, RXC007 must be taken approximately 12 hours apart between the morning and evening doses and patients must eat their meal as described

above, 30 minutes prior to the evening dose of RXC00

<b>Arm title</b>	RXC007 50 mg Open label extension
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	RXC007
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

RXC007 was administered orally as capsules twice daily (BID) at fixed doses of 20 mg or 50 mg for 12 weeks during the double-blind treatment period.

<b>Number of subjects in period 2</b>	RXC007 20 mg Open label extension	RXC007 50 mg Open label extension
Started	10	14
Completed	10	14

## Baseline characteristics

### Reporting groups

Reporting group title	RXC007 20 mg
Reporting group description: Subjects received RXC007 20 mg twice daily for 12 weeks during the double-blind period and could remain on stable background antifibrotic therapy (nintedanib or pirfenidone) if applicable."	
Reporting group title	RXC007 50 mg
Reporting group description: Subjects received RXC007 50 mg twice daily for 12 weeks during the double-blind period and could remain on stable background antifibrotic therapy (nintedanib or pirfenidone) if applicable	
Reporting group title	Placebo
Reporting group description: -	

Reporting group values	RXC007 20 mg	RXC007 50 mg	Placebo
Number of subjects	18	18	12
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	5	4	2
From 65-84 years	13	14	10
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	69.4	69	70.8
standard deviation	± 5.88	± 6.52	± 6.06
Gender categorical			
Units: Subjects			
Female	3	3	5
Male	15	15	7

Reporting group values	Total		
Number of subjects	48		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	11		

From 65-84 years	37		
85 years and over	0		

  

Age continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	11		
Male	37		



## End points

### End points reporting groups

Reporting group title	RXC007 20 mg
Reporting group description: Subjects received RXC007 20 mg twice daily for 12 weeks during the double-blind period and could remain on stable background antifibrotic therapy (nintedanib or pirfenidone) if applicable."	
Reporting group title	RXC007 50 mg
Reporting group description: Subjects received RXC007 50 mg twice daily for 12 weeks during the double-blind period and could remain on stable background antifibrotic therapy (nintedanib or pirfenidone) if applicable	
Reporting group title	Placebo
Reporting group description: -	
Reporting group title	RXC007 20 mg Open label extension
Reporting group description: -	
Reporting group title	RXC007 50 mg Open label extension
Reporting group description: -	

### Primary: Incidence of adverse events and tolerability of RXC007 after 12 weeks of twice-daily oral dosing in subjects with idiopathic pulmonary fibrosis.

End point title	Incidence of adverse events and tolerability of RXC007 after 12 weeks of twice-daily oral dosing in subjects with idiopathic pulmonary fibrosis.
End point description: Safety and tolerability assessed through incidence, severity, and relationship of TEAEs, SAEs, and discontinuations due to adverse events.	
End point type	Primary
End point timeframe: Baseline to week 12.	

End point values	RXC007 20 mg	RXC007 50 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18	18	12	
Units: Number of subjects	15	15	7	

### Statistical analyses

Statistical analysis title	TEAEs,SAE and AE
Statistical analysis description: Incidence of TEAEs and SAEs summarized as number (%) of subjects by treatment group	
Comparison groups	RXC007 20 mg v RXC007 50 mg v Placebo

Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.9999 <sup>[1]</sup>
Method	Descriptive summary statistics

Notes:

[1] - Not applicable

### Secondary: Change from baseline in percent predicted and absolute forced vital capacity (FVC) at Week 12.

End point title	Change from baseline in percent predicted and absolute forced vital capacity (FVC) at Week 12.
-----------------	--

End point description:

Spirometry was performed at baseline and Week 12 to assess change in FVC % predicted, a measure of pulmonary function. The LS Mean change from baseline was compared between RXC007 and placebo using ANCOVA.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 12.

End point values	RXC007 20 mg	RXC007 50 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	17	12	
Units: percent				
least squares mean (standard error)	-1.55 (± 0.86)	-3.00 (± 0.83)	-3.50 (± 0.90)	

### Statistical analyses

Statistical analysis title	Primary Analysis of Efficacy analysis
Comparison groups	RXC007 20 mg v RXC007 50 mg v Placebo
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1226
Method	Mixed models analysis
Parameter estimate	Mean difference (net)

### Secondary: Pharmacokinetic parameters of RXC007 (AUC– h, Cmax, Tmax)\_after multiple oral doses\_C1D1

End point title	Pharmacokinetic parameters of RXC007 (AUC– h, Cmax, Tmax)_after multiple oral doses_C1D1
-----------------	--

End point description:

Plasma RXC007 concentrations were measured at predefined timepoints to calculate pharmacokinetic parameters (AUC– h, Cmax, Tmax).

End point type	Secondary
----------------	-----------

End point timeframe:

This was assessed at 2 time points: Cycle 1 Day 1 (Baseline) and Cycle 1 Day 8  
(The plasma PK parameters derived for RXC007 are summarised in Table 15 in the CSR for C1D1 and C1D8)

End point values	RXC007 20 mg	RXC007 50 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18	18	0 <sup>[2]</sup>	
Units: AUC– h = ng·h/mL; Cmax = ng/mL; Tmax				
geometric mean (geometric coefficient of variation)	241 (± 29)	564 (± 27.8)	()	

Notes:

[2] - PK not assessed for placebo. RXC007 is not given

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic parameters of RXC007 (AUC– h, Cmax, Tmax)\_after multiple oral doses\_C1D8

End point title	Pharmacokinetic parameters of RXC007 (AUC– h, Cmax, Tmax)_after multiple oral doses_C1D8
End point description:	
End point type	Secondary
End point timeframe:	
Cycle 1 Day 8 ( C1D8)	

End point values	RXC007 20 mg	RXC007 50 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18	18	12	
Units: AUC– h = ng·h/mL; Cmax = ng/mL; Tmax				
geometric mean (geometric coefficient of variation)	332 (± 37)	791 (± 30.4)	0 (± 0)	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Treatment-emergent adverse events (TEAEs) were summarised for events that occurred from the first dose of study drug up to 28 days after the last dose.

Adverse event reporting additional description:

Adverse events were monitored from consent to end of follow-up. Investigators questioned subjects at each visit, reviewed vitals, labs, and ECGs, and recorded all TEAEs in the eCRF. Events were coded with MedDRA, graded by CTCAE guide, and reviewed by the Data Review Committee.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	25

### Reporting groups

Reporting group title	RXC007 20 mg BID
-----------------------	------------------

Reporting group description:

Subjects received RXC007 20 mg twice daily for 12 weeks during the double-blind treatment period.

Reporting group title	RXC007 50 mg BID
-----------------------	------------------

Reporting group description:

Subjects received RXC007 50 mg twice daily for 12. weeks during the double-blind treatment period

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received matching placebo tablets twice daily for 12 weeks during the double-blind treatment period.

Serious adverse events	RXC007 20 mg BID	RXC007 50 mg BID	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 18 (11.11%)	1 / 18 (5.56%)	0 / 12 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Nervous system disorders			
Ischaemic attack			
subjects affected / exposed	1 / 18 (5.56%)	0 / 18 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Viral pneumonia and Dyspnoea			
subjects affected / exposed	0 / 18 (0.00%)	1 / 18 (5.56%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	1 / 18 (5.56%)	0 / 18 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	RXC007 20 mg BID	RXC007 50 mg BID	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 18 (11.11%)	0 / 18 (0.00%)	1 / 12 (8.33%)
Respiratory, thoracic and mediastinal disorders			
Cough,Dyspnoea			
subjects affected / exposed	2 / 18 (11.11%)	0 / 18 (0.00%)	1 / 12 (8.33%)
occurrences (all)	2	0	1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 April 2023	<ul style="list-style-type: none"><li>• Summary of safety data from the Phase 1 study updated following completion of MAD cohorts</li><li>• Update of inclusion criteria# 3 and 4 (and assessment of efficacy text) to clarify on use of histopathology to confirm UIP diagnosis in the case of indeterminate HRCT central read assessments</li><li>• Clarification on Cohort 3 dosing in the event a lower dose was selected</li><li>• Text added to state EOT visit in the translational science sub study should be Cycle 2 Day 1 if the patient did not continue past 28 days dosing. Further clarification on EOT visit for main study and first study visit for OLE</li><li>• Plans for dose escalation/dose review amended: Dose review committee meeting text updated with respect assessment of safety data and ad hoc meetings; updated wording on dose escalation stopping criteria; clarification on causal relationship of events, and that exact preferred term match was not needed to be considered same events</li><li>• Amended stopping rules so that they applied at any point in the treatment period, confirmed that treatment was to be discontinued in cases in Hy's law, and provided clarification on causal relationship</li><li>• Segregation of main study and OLE in the trial timetable for clarity, with new section added to explain OLE schedule of visits further, and new Appendix 3 added (separate SoA for OLE)</li><li>• Correction of sampling timepoints for spirometry and DLCO. Correction of bronchoscopy sampling days in the translational sub study</li></ul>
21 July 2023	<ul style="list-style-type: none"><li>• Addition of PBMC collection at selected sites as exploratory objective/endpoint of the main study</li><li>• Clarified that bronchial absorption samples in the translation sub study were to be collected at selected sites only</li><li>• Clarified that the translation sub-study was no longer to run in parallel with the main study and that it may run in up to 2 cohorts (up to 16 patients</li><li>• Plans for dose escalation/dose review amended, so information regarding progression to cohort 3b (translational sub study) removed. Clarified that additional patients could be randomised to lower doses</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported